Equities research analysts expect that Curis, Inc. (NASDAQ:CRIS) will announce earnings per share of ($0.08) for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Curis’ earnings. Curis reported earnings per share of ($0.11) in the same quarter last year, which suggests a positive year over year growth rate of 27.3%. The business is scheduled to report its next quarterly earnings results on Thursday, May 3rd.
According to Zacks, analysts expect that Curis will report full-year earnings of ($0.38) per share for the current fiscal year, with EPS estimates ranging from ($0.44) to ($0.34). For the next financial year, analysts anticipate that the business will post earnings of ($0.41) per share, with EPS estimates ranging from ($0.45) to ($0.34). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover Curis.
Curis (NASDAQ:CRIS) last issued its quarterly earnings data on Thursday, March 8th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.04. Curis had a negative net margin of 538.66% and a negative return on equity of 250.55%. The company had revenue of $3.26 million during the quarter, compared to the consensus estimate of $2.03 million. During the same quarter last year, the company earned ($0.08) earnings per share.
Shares of NASDAQ:CRIS opened at $0.57 on Tuesday. The company has a current ratio of 4.56, a quick ratio of 4.56 and a debt-to-equity ratio of 1.49. Curis has a 52-week low of $0.47 and a 52-week high of $2.72.
Several hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. grew its position in shares of Curis by 2.3% during the fourth quarter. BlackRock Inc. now owns 9,719,497 shares of the biotechnology company’s stock worth $6,803,000 after buying an additional 223,002 shares in the last quarter. Millennium Management LLC boosted its holdings in Curis by 1,341.7% in the fourth quarter. Millennium Management LLC now owns 3,149,154 shares of the biotechnology company’s stock worth $2,204,000 after purchasing an additional 2,930,725 shares during the period. JPMorgan Chase & Co. boosted its holdings in Curis by 62,201.8% in the third quarter. JPMorgan Chase & Co. now owns 2,381,798 shares of the biotechnology company’s stock worth $3,691,000 after purchasing an additional 2,377,975 shares during the period. State Street Corp boosted its holdings in Curis by 10.4% in the second quarter. State Street Corp now owns 1,857,044 shares of the biotechnology company’s stock worth $3,511,000 after purchasing an additional 175,424 shares during the period. Finally, Renaissance Technologies LLC boosted its holdings in Curis by 2,389.5% in the fourth quarter. Renaissance Technologies LLC now owns 1,331,900 shares of the biotechnology company’s stock worth $932,000 after purchasing an additional 1,278,400 shares during the period. 47.66% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This piece was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://www.tickerreport.com/banking-finance/3334817/0-08-eps-expected-for-curis-inc-cris-this-quarter.html.
Curis, Inc, a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.